Clinical trial
Phase 2 Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
NCT05135975 is registered in ClinicalTrials.gov with Nationwide Children's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2 Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
- Lead sponsor
- Nationwide Children's Hospital
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- July 20, 2022
- Completion date
- December 31, 2029
- Enrollment
- 86 (estimated)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.